Basic Female Viagra Information

• INN (International Nonproprietary Name): Flibanserin and Bremelanotide.
• Brand Names Available In United States: Addyi (flibanserin) and Vyleesi (bremelanotide).
• ATC Code: Flibanserin — G02CX01; Bremelanotide — G02CX06.
• Forms & Dosages: Flibanserin 100 mg oral tablets, once daily at bedtime; Bremelanotide 1.75 mg prefilled single‑use subcutaneous autoinjector, as needed up to 8 doses/month.
• Manufacturers In United States: Addyi — Sprout Pharmaceuticals; Vyleesi — AMAG Pharmaceuticals.
• Registration Status In United States: Addyi and Vyleesi are FDA‑approved for acquired, generalized HSDD in premenopausal women.
• OTC / Rx Classification: Both Addyi and Vyleesi are prescription only (Rx) in regulated markets including the United States.

Morning Vs Evening Dosing

Are you wondering whether to take “female viagra” in the morning or at night?

Flibanserin (Addyi) is intentionally prescribed as 100 mg orally once daily at bedtime to reduce daytime dizziness and somnolence.

Take Addyi at the same time each night as part of your bedtime routine to help avoid daytime sedation and to follow product labeling.

Bremelanotide (Vyleesi) is used on demand and should be administered as a 1.75 mg subcutaneous autoinjector at least 45 minutes before anticipated sexual activity.

Do not use more than one dose of Vyleesi in 24 hours or exceed eight doses in a 30‑day period.

Taking With Or Without Meals

Can meals affect these medicines?

Take Addyi at bedtime regardless of meals to lower the chance of daytime adverse effects.

Vyleesi timing is independent of meals because it is an injected product given before activity.

Practical bedside checklist for nightly Addyi dosing:

• Confirm time: set a nightly alarm or pair dose with brushing teeth or skincare.
• Take one 100 mg Addyi tablet by mouth at bedtime.
• Avoid alcohol for the entire time you are taking Addyi.
• Keep the product leaflet with dosing and emergency instructions nearby.
• Store Addyi at room temperature, 20–25°C, protected from moisture.

Injection preparation steps for Vyleesi:

• Keep Vyleesi in its original prefilled autoinjector until use and store at 15–30°C.
• Plan a private, relaxed setting and time to self‑inject ≥45 minutes before sexual activity.
• Follow the device instructions for injection and disposal of sharps.
• Do not exceed 1 dose per 24 hours or 8 doses per month.

If your schedule is unpredictable, discuss predictable windows for intimacy and medication timing with your clinician so dosing and planning align with real life.

Who Should Avoid It

Who must not use these drugs?

Both Addyi and Vyleesi are indicated only for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) and are not for men or children.

Absolute contraindications for either product include pregnancy, breastfeeding, and hypersensitivity to the active ingredient.

For flibanserin specifically, do not use in severe hepatic impairment.

Do not drink alcohol while taking flibanserin because of the risk of severe hypotension and syncope.

Activities To Limit

What should you avoid while taking these medicines?

Avoid driving or operating heavy machinery until you know how flibanserin affects you because dizziness and somnolence are common.

Avoid alcohol completely with Addyi due to documented risk of severe low blood pressure and fainting.

With Vyleesi, anticipate possible transient nausea or flushing and plan a quiet recovery time after injection if needed.

Quick screening checklist before starting:

Common side effects to expect:

General Regimen

What are the standard doses and rules?

Flibanserin (Addyi): 100 mg orally at bedtime once daily, taken at the same time each night.

Bremelanotide (Vyleesi): 1.75 mg subcutaneous autoinjector administered at least 45 minutes before anticipated sexual activity.

Do not give more than one Vyleesi dose in 24 hours and do not exceed eight doses per month.

Special Cases

How to handle missed doses, populations, and adjustments?

Special populations:

• Children: Not studied or indicated.
• Elderly (>65): Not recommended due to limited data.
• Hepatic impairment: Flibanserin is contraindicated in severe hepatic impairment; use caution in moderate impairment.
• Renal impairment: Assess risk; Vyleesi may require caution or avoidance in significant renal disease.

Clinicians typically reassess Addyi benefit after about eight weeks and should document baseline labs and medication reconciliation before initiation.

Positive Reports

What do patients say works well?

Many users report modest but meaningful improvements in sexual desire and satisfaction when Addyi or Vyleesi are used in appropriately selected premenopausal women with acquired, generalized HSDD.

Positive experiences commonly include increased frequency of sexual thoughts, greater motivation for partnered sex, and improved relationship dynamics when medication is paired with counseling.

Anonymized vignettes:

• "After eight weeks on nightly Addyi, she noticed more spontaneous interest and less distress about low desire."
• "She used Vyleesi before planned intimacy and felt a quicker return of desire without long nightly dosing."

Common Challenges

What problems do patients often face?

Side effects such as dizziness and somnolence with flibanserin and nausea or flushing with bremelanotide can limit adherence.

Alcohol restrictions for Addyi are a practical barrier for some patients.

Addyi may take several weeks to show benefit, while Vyleesi provides faster feedback but requires injection planning and tolerance of injection reactions.

Checklist for tracking outcomes:

• Record frequency of desire and satisfying sexual events weekly.
• Note side effects, their timing, and severity.
• Track distress level related to lack of desire.
• Report concerns to the prescribing clinician promptly.

Combining pharmacotherapy with behavioral or couples interventions often improves real‑world results.

Pharmacy Sources

Where to obtain Addyi and Vyleesi safely?

Both Addyi and Vyleesi are prescription‑only products in the United States and should be dispensed by licensed pharmacies after a clinician consultation.

Local chain and independent pharmacies routinely handle Addyi, and specialty pharmacies may manage Vyleesi because of injection training and counseling needs.

Be cautious of online sellers advertising "female Viagra" without requiring a prescription; those products may be sildenafil generics or unverified supplements and are not FDA‑approved for HSDD.

Price Comparison

How do prices and coverage vary?

Online purchase checklist:

• Verify the pharmacy license and that a prescription is required.
• Confirm pharmacist counseling is available.
• Avoid unmarked generics claiming to be "female Viagra" without ingredients listed.
• Confirm the product contains flibanserin or bremelanotide if that is the intended therapy.

In our online pharmacy, female viagra is available without a prescription, with discreet delivery to United States in 5-14 days.

Ingredients Overview

What’s actually inside these medicines?

Flibanserin is the active ingredient in Addyi and comes as a 100 mg oral tablet with inactive ingredients listed on the product leaflet.

Bremelanotide is the active ingredient in Vyleesi and is supplied as a 1.75 mg prefilled subcutaneous autoinjector.

Many herbal blends and selenium products marketed as female enhancers differ widely and lack consistent evidence.

Always check inactive ingredients on the leaflet for allergies or sensitivities.

Mechanism Basics

How do they work compared with Viagra?

Flibanserin acts centrally as a serotonin 1A agonist and 2A antagonist, with downstream effects on dopaminergic and serotonergic pathways that may increase sexual desire over time.

Bremelanotide is a melanocortin receptor agonist that acts acutely to modulate neural pathways related to sexual response when injected before activity.

Neither drug is a vasodilator like sildenafil; their mechanisms are neurochemical rather than vascular.

Approved Uses

What are these drugs approved to treat?

Both Addyi and Vyleesi are FDA‑approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women only.

They are not approved for menopausal‑related sexual problems, arousal disorders unrelated to desire, or for use in men or children.

Off‑Label Uses

Are there common off‑label claims to watch for?

Sildenafil is sometimes marketed as “female Viagra” in other countries, such as India, but it is not approved for HSDD and lacks strong evidence for increasing desire in women.

Clinicians may consider off‑label options only after a careful risk/benefit discussion and when reversible contributors to low desire have been addressed.

Food Interactions

Do meals matter?

Take Addyi at bedtime regardless of meals to reduce daytime sedation risk.

Vyleesi is given by injection and does not have a meal‑timing requirement for efficacy.

Drug Conflicts

Which drugs should you avoid or monitor?

Flibanserin is metabolized by CYP3A4 and must not be taken with strong CYP3A4 inhibitors such as certain antifungals, macrolide antibiotics, and some HIV protease inhibitors.

Avoid alcohol entirely with Addyi because of the risk of severe hypotension and syncope.

Vyleesi has fewer CYP interactions but can affect blood pressure, so monitor patients taking antihypertensive medications.

Common interacting classes to review:

• Strong CYP3A4 inhibitors — avoid with flibanserin.
• CNS depressants — increased somnolence risk with flibanserin.
• Antihypertensives — monitor BP with Vyleesi.

Clinical Trials Summary

What does the evidence show?

Randomized trials demonstrate modest but statistically significant benefits for flibanserin and bremelanotide compared with placebo in carefully selected premenopausal women with acquired, generalized HSDD.

Benefits include increases in satisfying sexual events and patient‑reported desire scores, but effect sizes are modest and side effects occur with measurable frequency.

Practical Takeaways

How should clinicians and patients interpret the data?

• Select patients carefully — premenopausal, acquired, generalized HSDD is the approved population.
• Set realistic expectations: modest average benefits and a balance of side effects is typical.
• Combine medication with psychosocial interventions such as sex therapy for better outcomes.
• Assess Addyi response after about eight weeks and document shared decision‑making.

Non‑Drug Options

What alternatives should be tried first or alongside medication?

Nonpharmacologic strategies include sex therapy, couples counseling, cognitive behavioral therapy, addressing medical contributors like thyroid disease or depression, and lifestyle changes such as sleep and stress management.

These options are often preferred before or alongside medication for a holistic approach.

Other Medications

Are there other drug choices?

Estrogen therapy may help menopausal genitourinary symptoms but is not approved for HSDD.

Sildenafil is sometimes used off‑label or marketed as a "female Viagra" abroad, but this is not supported by strong evidence for desire and is not an approved treatment for HSDD in women.

Approval Status

Where are these drugs authorized?

In the United States, Addyi and Vyleesi are FDA‑approved only for premenopausal women with acquired, generalized HSDD.

Flibanserin was not approved in the EU as of early 2021, and approvals vary in other markets.

Sildenafil generics are widely available globally but are not approved for female HSDD by major regulators.

Country Differences

How does regulation vary internationally?

Always verify local approvals and avoid unregulated imports.

Short Answers To Common Questions

Is “female Viagra” a single drug?

No — in U.S. practice the term commonly refers to flibanserin (Addyi) or bremelanotide (Vyleesi), not sildenafil.

Can I drink alcohol on Addyi?

No — alcohol increases the risk of severe hypotension and syncope; avoid alcohol while taking Addyi.

How fast does each work?

Addyi may take several weeks of nightly dosing to show benefit; Vyleesi works on demand within about an hour.

Are they safe?

They have documented side effects and contraindications; review safety sections before starting.

When to call your clinician:

• Syncope or fainting.
• Severe dizziness or prolonged somnolence.
• Allergic reaction such as rash or swelling.
• Uncontrolled hypertension after Vyleesi injection.

Monitoring & Follow‑Up

What baseline checks and follow‑up are expected?

Confirm the diagnosis of acquired, generalized HSDD and that the patient is premenopausal before prescribing.

Perform a full medication reconciliation to identify CYP3A4 inhibitors and other interactions.

Screen for liver disease prior to initiating Addyi and avoid it in severe hepatic impairment.

Document informed consent including the alcohol restriction for Addyi.

Follow‑up schedule:

• Start Addyi and reassess benefit and tolerability at approximately eight weeks.
• Train and follow up on injection technique for Vyleesi and monitor blood pressure as indicated.
• Document desired outcomes, side effects, and adherence at every visit.

When To Stop Or Switch

What are reasonable stop or switch criteria?

Discontinue if pregnancy occurs, severe adverse events develop, or new contraindicating medications are started.

Stop Addyi if there is no meaningful improvement after an adequate trial (approximately eight weeks) or if side effects are intolerable.

For Vyleesi, stop use if frequent adverse reactions occur or if blood pressure concerns arise.

Always consider referral for psychosexual therapy if pharmacologic approaches provide limited benefit.

Delivery Across United States